Compare with RAYMED LABS. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ZIM LABORATORIES vs RAYMED LABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ZIM LABORATORIES RAYMED LABS ZIM LABORATORIES/
RAYMED LABS
 
P/E (TTM) x 30.0 -5.2 - View Chart
P/BV x 1.2 - - View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ZIM LABORATORIES   RAYMED LABS
EQUITY SHARE DATA
    ZIM LABORATORIES
Mar-21
RAYMED LABS
Mar-20
ZIM LABORATORIES/
RAYMED LABS
5-Yr Chart
Click to enlarge
High Rs1313 4,548.4%   
Low Rs531 5,448.5%   
Sales per share (Unadj.) Rs189.20-  
Earnings per share (Unadj.) Rs4.5-0.1 -3,435.9%  
Cash flow per share (Unadj.) Rs14.2-0.1 -12,151.1%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs99.0-4.6 -2,130.4%  
Shares outstanding (eoy) m16.244.27 380.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.5NM-  
Avg P/E ratio x20.5-14.8 -138.3%  
P/CF ratio (eoy) x6.5-16.6 -39.1%  
Price / Book Value ratio x0.9-0.4 -224.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,4978 18,147.2%   
No. of employees `000NANA-   
Total wages/salary Rs m3580 223,518.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,0730-  
Other income Rs m230 17,976.9%   
Total revenues Rs m3,0960 2,381,538.5%   
Gross profit Rs m346-1 -54,892.1%  
Depreciation Rs m1580 263,150.0%   
Interest Rs m1090-   
Profit before tax Rs m102-1 -18,269.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m290-   
Profit after tax Rs m73-1 -13,067.9%  
Gross profit margin %11.3NM- 
Effective tax rate %28.50-   
Net profit margin %2.4NM- 
BALANCE SHEET DATA
Current assets Rs m1,9181 213,066.7%   
Current liabilities Rs m1,42022 6,338.1%   
Net working cap to sales %16.2NM- 
Current ratio x1.40 3,361.7%  
Inventory Days Days16NM- 
Debtors Days Days858NM- 
Net fixed assets Rs m1,3042 78,101.2%   
Share capital Rs m16243 380.0%   
"Free" reserves Rs m1,445-63 -2,309.2%   
Net worth Rs m1,608-20 -8,102.3%   
Long term debt Rs m2180-   
Total assets Rs m3,2223 125,365.4%  
Interest coverage x1.9NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x1.00-   
Return on assets %5.7-21.7 -26.1%  
Return on equity %4.62.8 162.2%  
Return on capital %11.62.8 412.4%  
Exports to sales %67.4NM-  
Imports to sales %4.1NM-  
Exports (fob) Rs m2,072NA-   
Imports (cif) Rs m127NA-   
Fx inflow Rs m2,1400-   
Fx outflow Rs m1270-   
Net fx Rs m2,0120-   
CASH FLOW
From Operations Rs m3190-  
From Investments Rs m-59NA-  
From Financial Activity Rs m-260NA-  
Net Cashflow Rs m-10-  

Share Holding

Indian Promoters % 33.3 28.4 117.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 1.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 66.7 71.6 93.2%  
Shareholders   4,610 1,428 322.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ZIM LABORATORIES With:   VENUS REMEDIES  MARKSANS PHARMA.  NUTRAPLUS PR  AMI ORGANICS  SUVEN PHARMACEUTICALS  



Today's Market

5 Reasons Why Sensex Crashed, Tarsons Products' Lukewarm Debut, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended deep in the red on Friday. Benchmark indices slipped nearly 3% on the back of a global sell-off following the emergence of new variant of Coivd-19.

Related Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Don't Sell these Stocks if the Market Falls(Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

How to Find Your Next 10-Bagger in this Market(Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ZIM LABORATORIES SHARE PRICE


Nov 26, 2021 (Close)

TRACK ZIM LABORATORIES

  • Track your investment in ZIM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ZIM LABORATORIES

ZIM LABORATORIES 8-QTR ANALYSIS

COMPARE ZIM LABORATORIES WITH

MARKET STATS